All News

The ACIP recommendations are designed to improve access to RSV vaccination, emphasizing the need to get vaccinated.

Pharmacists can play a crucial role in diabetes management by implementing standing order protocols for medication titration and serving as a bridge between patients and other health care providers.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.

This narrative review dispels the long-held belief that reduction in salt intake leads to better health outcomes in patients with heart failure.

Many patients who took technosphere insulin saw improvements in hemoglobin A1c, but other patients saw worsening with the drug.

Antibody-drug conjugates (ADCs) revolutionize cancer therapy by delivering powerful drugs directly to tumors and minimize damage to healthy cells.

The UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) introduced changes to streamline its drug approval processes.

Explore the definition of digiceuticals, current digiceutical products available, and pharmacy implications.

As dupilumab garners positive clinical trial results in patients with chronic obstructive pulmonary disease, it is increasingly important that pharmacists educate themselves on the treatment.

Pharmacists can play a critical role in addressing food insecurity in their communities, with a variety of tools at their disposal.

Jacqueline Bainbridge from the University of Colorado discussed what it meant to one of the recipients of the 2024 Giants of MS awards.

The test can be performed in settings that operate under the Clinical Laboratory Improvement Amendments waiver, including community pharmacies.

Pharmacists are leveraging tools, campaigns, and free samples to educate patients about medication-induced photosensitivity and the importance of sun protection.

The CATALYST trial has identified hypercortisolism as a significant factor in approximately 1.2 to 1.3 million poorly controlled diabetes patients in the United States.

Palliative care may help reduce symptoms and improve quality-of-life for patients with cardiovascular disease.

Omar Nadeem, MD, discusses positive outcomes associated with GPRC5D-targeted CAR T-cell therapy.

Validating language proficiency in bilingual pharmacists is crucial for patient safety and communication.

The results are promising for patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma, and the trial is ongoing to assess the efficacy of odronextamab in other subtypes.

Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.

However, more research is needed to effectively integrate this biomarker into individualized asthma management strategies for pediatric patients.

By taking a research-based approach, clinical trials can become more diverse and better serve the needs of all individuals.

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

The findings suggest that exploring gender identity is a normal part of adolescent development for some youths.

Artificial intelligence (AI) may optimize cash pricing strategies in community pharmacies.

Pennsylvania, California, and New York were within the top 3 states, according to the findings.

The committee, after being presented evidence by the working group, recommended the vaccine for adults aged 65 and older and those 19 or older who have current recommendations to receive a pneumococcal vaccine.

In a rare case of non-tumor anti-Tr/DNER antibody-associated ataxia, the patient is treated with plasmapheresis and intravenous immunoglobulin (IVIG) for symptoms such as dysarthria and difficulty walking.

The designation was approved based on interim data from a phase 1 study that assessed SV-102 among males with metastatic castrate-resistant prostate cancer (mCRPC).

This is the first novel, precision mechanism of action to be released to treat patients with CIDP in over 3 decades.